Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

IBM and Swiss Hospital Test New Tool for Diagnosing Cancer

Published: Thursday, October 24, 2013
Last Updated: Thursday, October 24, 2013
Bookmark and Share
The compact and easy-to-use device may help unravel tumor heterogeneity and assist in personalized treatment strategies.

IBM scientists are collaborating with pathologists at the University Hospital Zürich to test a new proto-type tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

A critical step in the diagnosis of cancer is the analysis of a patient's biopsy tissue sample, which sometimes can be as small as a pinhead. Even with such a small sample, pathologists can test for the absence or presence of tumor cells and provide important information pertaining to the course of treatment to doctors.

To analyze samples, pathologists typically stain the tissue sample with liquid reagents. The intensity and distribution of the color stain classify and determine the extent of the disease. While this approach provides insights into the tumor, it is increasingly being realized that significant variations exist within the tumor itself; mapping these variations may help understand the drivers for each tumor, and consequently assist in personalizing treatment strategies.

Based on decades of experience in designing silicon computer chips, IBM scientists have developed an innovative technology called a microfluidic probe which can interact with tissue sections at the micrometer scale to help unravel some of the molecular variations within tumors.

The collaboration between IBM and the University Hospital Zürich puts a strong emphasis on uncovering the heterogeneity of tumors. More specifically, the collaboration focuses on lung cancer, which is one of the most prevalent forms of cancer and has a high mortality rate.

“Pathologists are determined to obtain as much accurate information as possible from markedly small biopsy samples”, said Prof. Dr. Alex Soltermann, a pathologist specializing in lung cancer at the Institute for Surgical Pathology of the University Hospital Zürich. “We hope to introduce new technologies, such as the microfluidic probe, into the clinical molecular pathology diagnostic framework to enable a range of investigations, which were previously thought to be infeasible. If we are successful, the tool will be a driver for personalized medicine, and translate into increased confidence in diagnosis and better detection of predictive cancer markers.”

Privatdozent Dr. Peter Schraml, director of the tissue biobank at the Institute of Surgical Pathology, University Hospital Zürich, said, “In addition to assisting in diagnostics, this tool may provide insight into the biomarker distribution in tumor tissues, which can aid in understanding cancer progression.”

The eight-millimeter-wide, diamond-shaped probe consists in its simplest form of a silicon microfluidic head ending with a small tip bearing two microchannels.

“For about a year we have been testing the probe in our lab, and initial results are very encouraging – we are now developing the technology in the context of important aspects in pathology” said Dr. Govind Kaigala, a scientist at IBM Research – Zurich. “Over the next several months, we will install a prototype device at the hospital and work alongside pathologists.”

The tool which houses the microfluidic probe was recently made significantly more compact and user-friendly and today is roughly the size of a tissue box – it is now at stage where it may assist in studying the distribution of low numbers of cancer cells in biopsied samples.

How does it work?

The probe injects very small volumes of reagents on the tissue surface and then continuously aspirates the reagents to prevent spreading and accumulation. This approach is used to deliver and retrieve reagents locally in selected areas of a tissue section with pinpoint accuracy. This local interaction with the tissue sample helps in mapping the heterogeneity in the tissue.

“We are very excited to partner with IBM on the microfluidic probe technology to develop techniques for its use in the clinical pathology framework – this is a fine example of a translational research that could also help answer some basic science questions” says Prof. Holger Moch, head of the Institute of Surgical Pathology at the University Hospital Zürich.

IBM scientists aspire to eventually partner with a medical equipment manufacturer to license the technology and bring it to market as a tool to assist pathologists in making challenging and critical decisions. The microfluidic probes are designed and manufactured at the Binnig and Rohrer Nanotechnology Center on the campus of IBM Research - Zurich.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Watson to Gain Ability to “See” with Planned $1B Acquisition of Merge Healthcare
Deal brings Watson technology together with leader in medical images.
Friday, August 07, 2015
IBM and Mars Launch Pioneering Effort to Drive Advances in Global Food Safety
New Sequencing the Food Supply Chain Consortium to undertake the largest-ever metagenomics study and unlock food safety insights across the supply chain.
Friday, February 06, 2015
IBM’s Big Data & Analytics Monitors Babies at INFANT Centre
INFANT Centre at University College Cork to use IBM Big Data & Analytics for real time monitoring of babies in neonatal intensive care.
Tuesday, January 27, 2015
The New York Genome Center and IBM Watson Group Collaborate
Project aims to apply advanced analytics to genomic treatment options for brain cancer patients.
Wednesday, September 10, 2014
Texas A&M System Teams with IBM to Drive Computational Sciences Research through Big Data and Analytics
The collaboration will leverage the power of big data analytics and high performance computing (HPC) systems.
Monday, February 03, 2014
IBM Commits $1.2 Billion to Expand Global Cloud Footprint, Builds Massive Network
IBM is committing to significantly expand its global network of cloud data centers.
Monday, January 27, 2014
IBM’s Biomedical Analytics Platform Helps Doctors Personalise Treatment
Italy’s Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments.
Tuesday, March 20, 2012
New Silicon Probe Assists in Disease Diagnostics and Drug Discovery
Scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately, reducing the need for large biopsy samples.
Monday, January 16, 2012
IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis
New advanced research effort to demonstrate a silicon-based “DNA Transistor” could help pave the way to read human DNA easily.
Thursday, October 08, 2009
IBM and University Researchers to Develop Research Tools to Improve Cancer Patient Outcomes
Advanced imaging and computer technologies aimed at providing for reliable prognosis leading to more personalized treatment.
Wednesday, February 13, 2008
IBM Discovery Could Shed Light on Workings of the Human Genome
IBM researchers discover numerous DNA patterns shared by areas of the human genome.
Wednesday, April 26, 2006
IBM Joins Forces with top Cancer Centers
IBM Collaborates with MSKCC, the Molecular Profiling Institute and Sainte-Justine Research Center.
Friday, November 11, 2005
IBM create smallest solid-state light emitter with Nanotubes

Thursday, May 08, 2003
IBM and IDBS Form Global Strategic Alliance

Wednesday, April 02, 2003
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos